L01EE01 • trametinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mitogen-activated protein kinase (MEK) inhibitors
Trametinib is a MEK kinase inhibitor used in the treatment of advanced or metastatic melanoma with BRAF V600 mutations. It works by blocking the MAPK/ERK signaling pathway, which is hyperactivated in tumor cells with BRAF mutations, thereby inhibiting their growth and proliferation.
Trametinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is often used in combination with dabrafenib, a BRAF inhibitor, to enhance treatment efficacy.
Common side effects include skin rashes, diarrhea, fatigue, nausea, and peripheral edema. In rare cases, severe adverse reactions such as cardiomyopathy, pulmonary function impairment, or ocular toxicity may occur. Regular monitoring of cardiac function and other clinical parameters is essential during treatment.
Trametinib is an innovative therapeutic option for patients with advanced melanoma, contributing to prolonged survival and improved quality of life.
Substance: trametinib
Date of last drug list: 01-12-2022
Commercial code: W62209002
Concentration: 1mg
Pharmaceutical form: tablets
Quantity: 30
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).